Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00149825
Status:
COMPLETED
Last Update Posted:
2014-05-20
First Post:
2005-09-06
Brief Title:
Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine the effectiveness of a combination of antidepressant medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression
Detailed Description:
Difficulties falling andor staying asleep are common in people who suffer from depression Persistent insomnia can hinder response to treatment In addition individuals whose insomnia does not resolve with standard antidepressant therapy are at increased risk for recurrence of their depression Between 60 and 84 of people who have major depressive disorder report symptoms of insomnia This study will assess the efficacy of combining antidepressant medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression
Participants in this double-blind study will be randomly assigned to receive either desensitization therapy or cognitive behavioral therapy to target insomnia All participants will also receive escitalopram oxalate an antidepressant medication The study will last 12 weeks The severity of participants depression and insomnia will be assessed Study visits will occur weekly for the first 6 weeks bi-weekly for the last 6 weeks and once 6 months post-intervention
Participants in this double-blind study will be randomly assigned to receive either desensitization therapy or cognitive behavioral therapy to target insomnia All participants will also receive escitalopram oxalate an antidepressant medication The study will last 12 weeks The severity of participants depression and insomnia will be assessed Study visits will occur weekly for the first 6 weeks bi-weekly for the last 6 weeks and once 6 months post-intervention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R21MH066131 | NIH | None | None |
| DSIR 83-ATAS | US NIH GrantContract | None | httpsreporternihgovquickSearchR21MH066131 |